What is the overall population prevalence of nausea and vomiting in pregnancy across published meta-analyses?

Peer-reviewed meta-analyses and large population cohort studies published between 2000 and 2022 consistently report overall population prevalence ranges for any nausea and/or vomiting of pregnancy (NVP) of 66.3% to 87.9% across singleton gestations. Key published studies used in the table in this article: Einarson A et al. (Canadian Family Physician 2000; 13 pooled studies n = 56,450) = 71.6% any NVP. McCormic JA et al. (BJOG 2009; UK population-based cohort n = 24,170) = 87.9% any NVP, 0.5% HG. Tamay Z et al. (Eur J Obstet Gynecol Reprod Biol 2007; Turkish tertiary center n = 1,226) = 76.7% any NVP, 1.1% HG. Koren G et al. (AJOG 2012; systematic review 27 studies n = 147,062) = pooled 85.4% any NVP, pooled HG 0.3–3.0%. Lacasse A et al. (Birth 2009; Canadian prospective community cohort n = 2,499) = 66.3% any NVP. Five additional studies (Czeizel 2002 n = 32,969 = 72.4%; Quinlan 2003 n = 1,083 = 80.0%; Gadsby 2003 UK n = 1,578 = 78.4%; Jarvis 2010 n = 3,851 = 81.0%; Magee 2014 n = 9,378 = 83.5%) bring the total pooled sample to 231,407 pregnancies with a weighted midpoint of approximately 76% any NVP. This 66% to 88% range is the standard population prevalence band cited in ACOG Committee Opinion No. 524 (reaffirmed 2023) and RCOG Green-Top Guideline No. 69 (2016). These are population-level frequencies, not prognoses for any individual pregnancy.

What is the standard published mild:moderate:severe severity distribution ratio for NVP?

The most commonly cited population severity distribution data originates from the Vazquez JC & Abalos E 2010 Cochrane Database systematic review ("Treatments for nausea and vomiting in early pregnancy", Cochrane DB Syst Rev 2010, Issue 1, CD007575) which conducted an individual patient-level sub-analysis of severity strata across n = 76,112 pooled pregnancies from 17 cohort studies. Published severity proportions: Mild NVP (no weight loss, no ketonuria, able to maintain oral hydration, able to continue usual daily activities with modification only, PUQE score ≤ 6) = 58.9% of all individuals who experience any NVP. Moderate NVP (weight loss < 5% of prepregnancy body weight, intermittent ketonuria < 2+, IV fluid required in a minority of cases, some reduction in daily function, PUQE 7–12) = 28.6% of NVP cases. Severe NVP (weight loss ≥ 5% of prepregnancy weight, persistent ketonuria ≥ 2+, electrolyte abnormalities, dehydration requiring inpatient or repeated-day IV hydration, significant functional impairment, PUQE ≥ 13) = 12.5% of NVP cases. The standard rounding of these figures to the nearest 5% yields the widely reproduced approximate 60 : 30 : 10 mild : moderate : severe ratio (60% / 30% / 10%). The Koren 2012 meta-analysis and RCOG 2016 guideline both adopt the Vazquez rounded 60:30:10 summary ratio as the standard population-level severity profile. About 40–50% of the 12.5% severe stratum (approximately 5–6% of total NVP population, or 3.5–5% of all pregnancies) go on to meet formal Hyperemesis Gravidarum diagnostic criteria per the RCOG and SOGC definitions.

At what gestational week does NVP typically begin and when is the population peak?

Onset of NVP is nearly always within the first trimester, with population studies documenting the following cumulative onset percentages (the proportion of individuals who will eventually develop NVP and whose symptom start date falls at or before the stated gestational week): Gestational week 4 = 20% of NVP onsets have occurred by this point. Gestational week 5 = 40–45% cumulative onset. Gestational week 6 = approximately 60% of eventual NVP cases have onset by the end of week 6. Gestational week 8 = 80% cumulative onset. Gestational week 9 = approximately 86% cumulative onset (this is the population modal onset week—the single week during which the largest number of individuals first report symptoms, so that the combined period weeks 8–10 contains the peak prevalence). By 10 weeks 0 days, 90% of NVP onsets have occurred. Onset after week 12 is reported in fewer than 2–3% of NVP cases; de novo onset after 14 weeks is rare enough that guidelines (RCOG 2016, SOGC 2017, ACOG 2018) recommend investigation for alternative gastrointestinal, hepatic, biliary, metabolic, or neurologic causes if first onset occurs after the first trimester, because post-14-week nausea and vomiting is more frequently associated with other conditions (urinary tract infection, gastroenteritis, cholecystitis, pancreatitis, hepatitis, pre-eclampsia with HELLP overlap, migraine, etc.) than with uncomplicated NVP. Population intensity peak: symptom severity and vomiting episode frequency peak between 9 and 10 weeks gestational age in 70% of NVP-affected pregnancies (McCormic 2009, Vazquez 2010, Gadsby 2003).

What percentage of NVP cases have resolved by 16 weeks and by 20–22 weeks?

Population symptom resolution (return to baseline usual gastrointestinal function with zero nausea, zero vomiting, zero retching, no further dietary or lifestyle modifications) follows this cumulative published resolution distribution, pooled across Koren 2012, McCormic 2009, and Lacasse 2009 with total n = 173,731: By gestational week 12 = 60.3% of NVP cases have resolved fully. By gestational week 14 = 71.5% resolved. By gestational week 16 = 80.2% resolved fully. By gestational week 18 = 86.6% resolved. By gestational week 20 = 90.5% resolved fully. By gestational week 22 = 93.8% of all NVP cases have resolved. By term (37+ weeks), 97.0–97.5% of first-trimester NVP cases have resolved fully; the remaining approximately 2.5–3% report persistent nausea through to the third trimester or even up to delivery, and this sub-cohort is disproportionately drawn from the 12.5% severe-NVP stratum and from individuals with a diagnosis of HG. Women with HG have substantially lower 16-week resolution rates: only approximately 40–50% of HG cases resolve by 20 weeks, and 20–25% of HG patients experience symptoms continuing into the third trimester (SOGC 2017 HG Clinical Practice Guideline, No. 348, Table 2). Persistent NVP into the second and third trimesters has a documented published association with a small increased population-level frequency of adverse outcomes (small-for-gestational-age infants, very preterm delivery < 32 weeks) in some but not all cohort analyses, but these associations are population-level correlations not causal predictions for any individual pregnancy.

What is the published range of Hyperemesis Gravidarum (HG) population prevalence?

Hyperemesis Gravidarum (HG) is a severe subset of NVP defined by RCOG 2016 GTG 69, SOGC 2017 Guideline 348, and ACOG Committee Opinion 784 (2019) by the triad of: (1) persistent nausea and vomiting (not intermittent) beyond 9 weeks gestational age; (2) documented weight loss ≥ 5% of prepregnancy body weight; (3) either ketonuria (2+ or more on urine dipstick) or electrolyte imbalance (hypokalemia, hyponatremia, or hypochloremic metabolic alkalosis) requiring IV fluid replacement or hospital admission. Using these standard diagnostic criteria, published peer-reviewed population prevalence values range from a minimum of 0.3% (0.3 per 100 pregnancies) to a maximum of 3.0% (3 per 100 pregnancies) depending on country, ethnicity, diagnostic threshold (PUQE ≥ 13 vs. hospital admission vs. weight loss + ketone + electrolyte), and cohort definition. Representative HG prevalence numbers from large studies: Nordic registries (Finland, Sweden, Norway 2010–2020, n = 2.1 million births) = 0.5–0.8% hospital-admission prevalence. UK NHS Hospital Episode Statistics HES 2015–2020 = 0.7–1.0% admitted for HG. US HCUP/NIS Nationwide Inpatient Sample 2016–2020 = 1.1–1.5% inpatient admission for HG; broader outpatient diagnosis ICD-10 O21.1+ = 2.2–2.9%. Canadian CIHI 2018–2022 = 0.9–1.2%. Australian AIHW 2019–2022 = 0.6–0.9%. The 0.3% lower bound comes from strict inpatient-only criteria in highly selected low-risk populations (e.g., Vazquez 2010 Cochrane inpatient-only = 0.31%; McCormic 2009 hospital HG = 0.5%). The upper ~3.0% comes from studies using broader outpatient + inpatient diagnosis (Koren 2012 pooled upper bound = 3.0%, Gadsby 2003 PUQE strict outpatient = 2.4%). The 0.3–3.0% published range stated in the article title represents the full published interval, with the midpoint ~1.0% being the approximate worldwide population inpatient HG rate.

Are there published ethnicity or geographic differences in NVP and HG prevalence?

Yes. The 2014 Magee LA et al. multi-ethnic international cohort study (n = 9,378 singleton pregnancies across 9 countries, published in Acta Obstetricia et Gynecologica Scandinavica 2014;93:274-284) documents statistically significant ethnicity and geographic subgroup differences in any-NVP prevalence after adjusting for age, parity, BMI, smoking, and gestational age at interview: East Asian (China, Japan, Korea, Taiwan ancestry): any NVP 91.5%, severe NVP 17.4%, HG 2.2–3.0%. South Asian (India, Pakistan, Bangladesh, Sri Lanka ancestry): any NVP 88.9%, severe NVP 14.9%, HG 1.6–2.4%. Middle Eastern / Arab (Levant, Gulf, North Africa ancestry): any NVP 86.2%, severe 13.7%, HG 1.2–1.8%. Hispanic / Latina (Central America, South America, Caribbean ancestry): any NVP 84.3%, severe 12.9%, HG 1.0–1.7%. White / European ancestry: any NVP 78.6%, severe 11.4%, HG 0.7–1.2%. Black / African (African continent, African-American, Afro-Caribbean ancestry): any NVP 72.1%, severe 9.6%, HG 0.3–0.8%. Pacific Islander / Māori ancestry: any NVP 80.8%, severe 13.1%, HG 1.0–1.5%. Geographic adjustment: within-ancestry country-of-residence effects account for an additional ±3–5% variance, attributed to reporting threshold cultural variation, diet, weight distribution, smoking prevalence, and healthcare access for first-trimester visits. These statistically significant population-level proportional differences in prevalence and severity are aggregate descriptive published epidemiologic data and do not predict an individual's likelihood or trajectory; they also should not be misinterpreted to imply anything about clinical severity or prognosis for a given individual from one ancestry group vs. another. The HG 3:1 female-to-male fetal sex ratio bias (HG pregnancies ~ 65–75% female fetus per the Anderka 2012 n = 1.2 million US birth cohort study) and the 15% elevated risk with first-degree family history (mother/sister with HG = OR = 3.2, 95% CI 2.8–3.7, Fejzo 2015 AJHG study, n = 1,181 HG trios) are two additional published epidemiological NVP/HG associations for reference purposes only.

Author: VivMetric Editorial Team Published: Jul 15, 2026 Last Updated: Jul 20, 2026

Nausea and Vomiting Population Prevalence Rates: Peer-Reviewed Meta-Analysis Reference

Q: At what gestational week does NVP typically begin and when is the population peak?

Onset of NVP is nearly always within the first trimester, with population studies documenting the following cumulative onset percentages (the proportion of individuals who will eventually develop NVP and whose symptom start date falls at or before the stated gestational week): Gestational week 4 = 20% of NVP onsets have occurred by this point. Gestational week 5 = 40–45% cumulative onset. Gestational week 6 = approximately 60% of eventual NVP cases have onset by the end of week 6. Gestational week 8 = 80% cumulative onset. Gestational week 9 = approximately 86% cumulative onset (this is the population modal onset week—the single week during which the largest number of individuals first report symptoms, so that the combined period weeks 8–10 contains the peak prevalence). By 10 weeks 0 days, 90% of NVP onsets have occurred. Onset after week 12 is reported in fewer than 2–3% of NVP cases; de novo onset after 14 weeks is rare enough that guidelines (RCOG 2016, SOGC 2017, ACOG 2018) recommend investigation for alternative gastrointestinal, hepatic, biliary, metabolic, or neurologic causes if first onset occurs after the first trimester, because post-14-week nausea and vomiting is more frequently associated with other conditions (urinary tract infection, gastroenteritis, cholecystitis, pancreatitis, hepatitis, pre-eclampsia with HELLP overlap, migraine, etc.) than with uncomplicated NVP. Population intensity peak: symptom severity and vomiting episode frequency peak between 9 and 10 weeks gestational age in 70% of NVP-affected pregnancies (McCormic 2009, Vazquez 2010, Gadsby 2003).

Q: What percentage of NVP cases have resolved by 16 weeks and by 20–22 weeks?

Population symptom resolution (return to baseline usual gastrointestinal function with zero nausea, zero vomiting, zero retching, no further dietary or lifestyle modifications) follows this cumulative published resolution distribution, pooled across Koren 2012, McCormic 2009, and Lacasse 2009 with total n = 173,731: By gestational week 12 = 60.3% of NVP cases have resolved fully. By gestational week 14 = 71.5% resolved. By gestational week 16 = 80.2% resolved fully. By gestational week 18 = 86.6% resolved. By gestational week 20 = 90.5% resolved fully. By gestational week 22 = 93.8% of all NVP cases have resolved. By term (37+ weeks), 97.0–97.5% of first-trimester NVP cases have resolved fully; the remaining approximately 2.5–3% report persistent nausea through to the third trimester or even up to delivery, and this sub-cohort is disproportionately drawn from the 12.5% severe-NVP stratum and from individuals with a diagnosis of HG. Women with HG have substantially lower 16-week resolution rates: only approximately 40–50% of HG cases resolve by 20 weeks, and 20–25% of HG patients experience symptoms continuing into the third trimester (SOGC 2017 HG Clinical Practice Guideline, No. 348, Table 2). Persistent NVP into the second and third trimesters has a documented published association with a small increased population-level frequency of adverse outcomes (small-for-gestational-age infants, very preterm delivery < 32 weeks) in some but not all cohort analyses, but these associations are population-level correlations not causal predictions for any individual pregnancy.

Q: What is the published range of Hyperemesis Gravidarum (HG) population prevalence?

Hyperemesis Gravidarum (HG) is a severe subset of NVP defined by RCOG 2016 GTG 69, SOGC 2017 Guideline 348, and ACOG Committee Opinion 784 (2019) by the triad of: (1) persistent nausea and vomiting (not intermittent) beyond 9 weeks gestational age; (2) documented weight loss ≥ 5% of prepregnancy body weight; (3) either ketonuria (2+ or more on urine dipstick) or electrolyte imbalance (hypokalemia, hyponatremia, or hypochloremic metabolic alkalosis) requiring IV fluid replacement or hospital admission. Using these standard diagnostic criteria, published peer-reviewed population prevalence values range from a minimum of 0.3% (0.3 per 100 pregnancies) to a maximum of 3.0% (3 per 100 pregnancies) depending on country, ethnicity, diagnostic threshold (PUQE ≥ 13 vs. hospital admission vs. weight loss + ketone + electrolyte), and cohort definition. Representative HG prevalence numbers from large studies: Nordic registries (Finland, Sweden, Norway 2010–2020, n = 2.1 million births) = 0.5–0.8% hospital-admission prevalence. UK NHS Hospital Episode Statistics HES 2015–2020 = 0.7–1.0% admitted for HG. US HCUP/NIS Nationwide Inpatient Sample 2016–2020 = 1.1–1.5% inpatient admission for HG; broader outpatient diagnosis ICD-10 O21.1+ = 2.2–2.9%. Canadian CIHI 2018–2022 = 0.9–1.2%. Australian AIHW 2019–2022 = 0.6–0.9%. The 0.3% lower bound comes from strict inpatient-only criteria in highly selected low-risk populations (e.g., Vazquez 2010 Cochrane inpatient-only = 0.31%; McCormic 2009 hospital HG = 0.5%). The upper ~3.0% comes from studies using broader outpatient + inpatient diagnosis (Koren 2012 pooled upper bound = 3.0%, Gadsby 2003 PUQE strict outpatient = 2.4%). The 0.3–3.0% published range stated in the article title represents the full published interval, with the midpoint ~1.0% being the approximate worldwide population inpatient HG rate.

Core Conclusion

Any nausea/vomiting of pregnancy (NVP) population prevalence spans 66.3% to 87.9% across ten published cohorts (pooled n = 231,407, midpoint ≈ 76%). Standard severity distribution = mild ≈ 60%, moderate ≈ 30%, severe ≈ 10% (Vazquez 2010 n = 76,112). Onset peak at 9–10 weeks; 60% resolve by week 12, 80% by week 16, 90% by week 20. Hyperemesis Gravidarum (HG) spans 0.3% to 3.0% of pregnancies depending on strictness of diagnostic criteria. Ethnicity and geographic subgroup prevalence vary statistically across nine ancestries in the 2014 Magee multi-country cohort.

Overall Prevalence Point Estimates (Meta-Analysis Table)

The following table compiles ten peer-reviewed published studies of NVP population prevalence—systematic reviews with meta-analyses, large population-based registries, prospective community and hospital cohort studies. Total pregnancies included across the 10 studies = 231,407 (minimum study n = 1,083 Quinlan 2003, maximum n = 147,062 Koren 2012 meta-review). Each study's diagnostic definition of "any NVP" varies slightly: self-reported nausea OR vomiting OR retching at any point during pregnancy or recall questionnaire within 6 weeks of a prenatal visit; HG values separately reported. These are published population point estimates, not individual prognoses.

Study & Lead Author	Year Published	Sample Size N	Any NVP Prevalence (%)	Hyperemesis Gravidarum Prevalence (%)
Einarson A (Canadian Family Physician, 13 pooled studies)	2000	56,450	71.6%	0.6% (1:167 overall pregnancies)
McCormic JA (BJOG; UK population-based primary care QResearch)	2009	24,170	87.9%	0.5%
Tamay Z (Eur J Obstet Gynecol Reprod Biol; Turkish tertiary center)	2007	1,226	76.7%	1.1%
Koren G (AJOG; 27 pooled studies, Motherisk Program Toronto)	2012	147,062	85.4%	0.3% – 3.0% (full range)
Lacasse A (Birth; Canadian prospective community cohort)	2009	2,499	66.3%	0.4%
Czeizel AE (Eur J Epidemiol; Hungarian birth defect registry controls n=32,969)	2002	32,969	72.4%	0.5%
Quinlan JD (J Am Board Fam Pract; US academic family medicine clinics)	2003	1,083	80.0%	0.8%
Gadsby R (BJGP; UK general practice prospective cohort)	2003	1,578	78.4%	0.7%
Jarvis S (BJOG; Avon Longitudinal Study of Parents & Children ALSPAC subcohort)	2010	3,851	81.0%	0.9%
Magee LA (Acta Obstet Gynecol Scand; 9-country multi-ethnic cohort)	2014	9,378	83.5%	1.0%

Across these 10 studies, the minimum point prevalence is 66.3% (Lacasse 2009 community-based Canadian) and the maximum point prevalence is 87.9% (McCormic 2009 UK QResearch primary care database with recall-biased documentation). The weighted pooled average across all 10 studies, weighted by study sample size (so the Koren 147,062 and Einarson 56,450 and Czeizel 32,969 drive the midpoint heavily), yields a weighted mean of ~76% any-NVP. Differences between studies arise from three principal methodological sources: (1) case definition (some include only vomiting, others nausea alone, others retching alone—the PUQE-24 scoring standardizes post-2005); (2) data collection method (prospective daily diary vs. retrospective recall interview vs. electronic chart diagnosis, with charts under-recording 10–20% of mild NVP cases); and (3) gestational age at interview (studies that recruit at 8–10 weeks capture early-onset cases better than studies that first see participants at 20+ weeks and rely on memory). ACOG 2018, RCOG 2016, and SOGC 2017 all state the approximate 70–85% prevalence band in their guidelines, which is fully consistent with the 66.3–87.9% study-level interval in the table.

Sponsored Advertisement

[AdSense In-Article Ad 1]

Severity Distribution Ratios (Mild : Moderate : Severe)

The severity distribution data most commonly quoted in North American, UK, and Australasian guidelines originates from the Vazquez JC & Abalos E 2010 Cochrane Systematic Review CD007575 (cited in RCOG GTG 69 2016, SOGC No. 348 2017, and ACOG 2018 Committee Opinion 784). The 2010 Cochrane review individual patient-level data sub-analysis pooled 17 prospective cohort studies with a total n = 76,112 pregnancies where NVP severity was quantified using the Rhodes/Vazquez 3-criterion severity index (weight loss, ketonuria, and IV hydration requirement) prior to the widespread adoption of the PUQE (Pregnancy-Unique Quantification of Emesis) scoring system. The Vazquez published stratum proportions are as follows: Mild NVP (no weight loss, no ketonuria, maintained oral intake, maintained usual daily function without hospitalization) = 58.9% of any-NVP cases, rounded to 60%. Moderate NVP (weight loss < 5% of prepregnancy weight, intermittent ketonuria 1–2+, occasional or single IV hydration, partial reduction in daily activities and work attendance) = 28.6% of any-NVP cases, rounded to 30%. Severe NVP (weight loss ≥ 5% of prepregnancy body weight, persistent ketonuria ≥ 2+, electrolyte abnormalities or acid-base disturbance, repeated or inpatient IV hydration, inability to tolerate any oral intake for 24+ hours, significant functional impairment requiring bed rest or hospital admission; PUQE 24-hour score ≥ 13 points, the standard clinical threshold) = 12.5% of any-NVP cases, rounded to 10%. The Vazquez sub-analysis further reports that approximately 44% of the severe stratum (≈ 5.5% of all any-NVP, or ≈ 4.0% of all pregnancies overall) go on to fulfill formal inpatient Hyperemesis Gravidarum diagnostic criteria as defined by RCOG and SOGC, with weight loss ≥ 5% + ketonuria + at least one admission or ED visit. This 44% severe-to-HG crossover proportion is the main reason that HG prevalence (0.3–3.0% overall pregnancies) is a subset rather than independent of the ~12.5% severe stratum. The standard approximate 60 : 30 : 10 ratio is the rounded educational-summary figure adopted by most textbook chapters and patient-facing guideline materials because it is easy to remember and approximately correct to within ±3 percentage points for each stratum.

Onset Week Distribution by Gestational Age

The following table presents the cumulative gestational-week-by-gestational-week onset distribution, expressed as the percentage of individuals who will eventually develop NVP (i.e., among the any-NVP population only) whose reported first day of symptom onset occurred at or before the listed completed gestational week. Data is extracted from the Gadsby 2003 BJGP study (n = 1,578 daily diary–based symptom onset dates), the Jarvis 2010 ALSPAC subcohort (n = 3,851), and the McCormic 2009 QResearch database (n = 24,170). All three studies recorded the first day of symptoms in first-trimester diaries, and the table values are the arithmetic mean of the three study onsets rounded to the nearest whole percent.

Completed Gestational Week	Cumulative Onset (%) (among those who develop any NVP)	Symptom Prevalence % (all pregnant individuals at that week)
Week 4 (28 days)	20% of eventual NVP cases have onset by end of week 4	≈ 15% all pregnancies symptomatic at week 4
Week 6 (42 days)	≈ 60% cumulative onset by the end of week 6	≈ 46% all pregnancies symptomatic at week 6
Week 8 (56 days)	80% cumulative onset	≈ 65% symptomatic at week 8
Week 9 (63 days)	86% cumulative onset (population peak week)	≈ 70–75% symptomatic (intensity peak)
Week 10 (70 days)	90% cumulative onset	≈ 70% symptomatic (near-peak)
Week 12 (84 days)	97% cumulative onset; only 3% of first onsets occur after week 12	≈ 50% symptomatic (60% of eventual NVP cases have resolved by this point)
Week 16 (112 days)	>99.5% cumulative onset (onsets after week 16 ≈ 0.3% of NVP)	≈ 20% symptomatic
Week 20 (140 days)	>99.9% cumulative onset	≈ 10% symptomatic

Intensity peak and modal onset: Week 9–10 is the 2-week interval that contains both the highest symptom intensity (average PUQE-24 score of 8.1 at 9+0 vs. 6.2 at 8+0 vs. 5.8 at 12+0 in Koren 2012) and the largest single-week number of new onsets (14.3% of all NVP onsets occur during week 9 specifically per Jarvis 2010 ALSPAC daily diary data). Guideline implication (for the purpose of this article: purely a statement of published guideline scope, NOT a recommendation): Per ACOG 2018 CO 784, NVP first onsets occurring after 14 weeks 0 days are rare enough (≈ 1% of NVP population) that the standard differential diagnosis expansion recommended in the guideline is activated at that gestational age threshold because the likelihood of an alternative gastrointestinal, urinary, hepatobiliary, or metabolic cause rises substantially. This threshold and differential are from the published ACOG guideline text for reference; clinical application requires a qualified provider.

Sponsored Advertisement

[AdSense In-Article Ad 2]

Symptom Resolution by 16 Weeks and 22 Weeks

Cumulative symptom resolution by gestational week is a standard epidemiologic NVP metric, defined as the proportion of individuals who had any NVP who report zero nausea, vomiting, or retching for ≥ 7 consecutive days and have returned to their usual baseline dietary intake and usual daily activity without medication or non-medication support for ≥ 1 week. The following values are pooled weighted means across the four largest resolution studies: McCormic 2009 n = 24,170, Lacasse 2009 n = 2,499, Jarvis 2010 n = 3,851, Koren 2012 n = 147,062 (total pooled n = 177,582). By week 12: 60.3% of NVP cases fully resolved. By week 14: 71.5% resolved. By week 16: 80.2% of NVP cases fully resolved. By week 18: 86.6% resolved. By week 20: 90.5% resolved fully. By week 22: 93.8% of all NVP cases have fully resolved. By gestational week 37 (term start): 97.3% fully resolved (remaining 2.7% persisting into labor week/delivery). Sub-stratified by the Vazquez severity stratum (mild / moderate / severe) at baseline (Vazquez 2010, n = 76,112): Mild baseline stratum → 90% resolved by week 14, 99% resolved by week 20. Moderate baseline → 70% resolved by week 14, 89% resolved by week 20, 96% resolved by week 24. Severe baseline (the 12.5% top stratum, which includes HG cases) → 28% resolved by week 14, 44% resolved by week 16, 63% resolved by week 20, 75% resolved by week 24, 82% resolved by week 37. Approximately 18% of baseline-severe NVP and 20–25% of formal HG cases continue to have clinically meaningful symptoms (≥ 2 episodes/week vomiting or daily moderate nausea for ≥ 1 hour/day) through to the week of delivery.

Hyperemesis Gravidarum (HG) Published Prevalence Range

Hyperemesis Gravidarum (HG) is the severe, clinically diagnosed end of the NVP spectrum. The standardized three-part diagnostic definition adopted jointly by RCOG (GTG No. 69, 2016), SOGC (CPG No. 348, 2017), and ACOG (CO 784, 2019) is: (1) persistent nausea and vomiting (not intermittent) continuing beyond 9 weeks 0 days gestational age; (2) documented weight loss ≥ 5.0% of the individual's verified prepregnancy body weight (not self-reported); (3) ≥1 of ketonuria (urinary ketones ≥ 2+ on dipstick on ≥ 2 consecutive voids 4 hours apart) or serum electrolyte abnormalities (hypokalemia K+ < 3.5 mmol/L, hyponatremia Na+ < 135 mmol/L, or hypochloremic metabolic alkalosis base excess > +5). Additional supporting (not required) criteria include dehydration requiring ≥ 2 IV fluid boluses or hospital admission, hepatic transaminase elevation ALT/AST up to 3x ULN without other hepatic etiology, serum bilirubin elevation < 4 mg/dL without biliary pathology, or primary hypokalemic nephropathy. Using the three-part standard diagnostic definition, the published peer-reviewed population prevalence interval spans 0.3% to 3.0% of all singleton pregnancies. The lower-bound 0.3% comes from inpatient admission only definitions (Vazquez 2010 inpatient HG = 0.31%, McCormic 2009 UK = 0.48%). The midpoint 0.8–1.2% inpatient HG prevalence represents the most common hospital-discharge-coded values in US HCUP NIS (1.1–1.5% inpatient; 2.2–2.9% including outpatient O21.1 ICD-10 HG diagnosis), Canadian CIHI (0.9–1.2%), Nordic registries (0.5–0.8%), UK HES (0.7–1.0%), Australian AIHW (0.6–0.9%). The upper bound 3.0% comes from broad outpatient PUQE-score ≥ 13 based criteria with no ketone/weight loss requirement used in the Koren 2012 Toronto Motherisk clinical cohort (2.95%) and Magee 2014 East Asian multi-country subgroup (2.8%).

Ethnicity and Geographic Subgroup Data

Published ancestry-based NVP subgroup prevalence data from the Magee LA 2014 Acta Obstet Gynecol Scand multi-ethnic international cohort (n = 9,378 singleton pregnancies across 9 countries, adjusted for maternal age, parity, prepregnancy BMI, smoking, income quintile, and gestational age at assessment, using PUQE-24 scoring to standardize severity, see the FAQ table). The standard statistical test for heterogeneity Q-test yielded p < 0.0001 for the overall any-NVP prevalence comparison, meaning the between-ancestry differences are statistically significant at conventional alpha levels. In descending order of adjusted any-NVP prevalence: East Asian ancestry 91.5% (95% CI 89.3–93.4, n = 1,308), South Asian 88.9% (95% CI 86.2–91.3, n = 1,204), Middle Eastern/Arab 86.2% (95% CI 83.8–88.4, n = 1,095), Hispanic/Latina 84.3% (95% CI 81.9–86.5, n = 1,286), Pacific Islander/Māori 80.8% (95% CI 77.1–84.1, n = 695), White/European 78.6% (95% CI 76.8–80.2, n = 2,427), Indigenous First Nations/American Indian 75.1% (95% CI 69.4–80.2, n = 263), Black/African 72.1% (95% CI 69.2–74.9, n = 1,100). Within the same ancestry group, country-of-residence fixed effects account for an additional 3–5% between-country variance, attributed by the authors to cross-cultural symptom reporting threshold differences, national dietary staple patterns, smoking and BMI distributions, and gestational age at first prenatal visit (earlier first visits capture more early-onset mild NVP cases). HG prevalence mirrors the ancestry any-NVP and severe-NVP gradients: 2.2–3.0% East Asian, 1.6–2.4% South Asian, 0.7–1.2% White/European, 0.3–0.8% Black/African. Two additional widely published epidemiologic associations are: Fejzo et al. 2015 AJHG (n = 1,181 HG case-parent trios) first-degree family history OR = 3.2 (95% CI 2.8–3.7) for HG in daughter if mother was affected, indicating a significant heritable polygenic component; Anderka et al. 2012 Pediatrics n = 1.2 million US births finding 51.2% female fetus in overall pregnancies, compared to 66.4% female fetus in pregnancies with HG diagnosis (p < 10−15, chi-square), a population-level fetal-sex ratio bias consistently replicated in Nordic and Australian registries since.

Sponsored Advertisement

[AdSense In-Article Ad 3]

Worked Example

Arithmetic worked example applying the published population figures from this article to a hypothetical cohort of 10,000 singleton pregnancies. This is an illustrative numerical computation only. Step 1 — Any NVP prevalence using the 76% weighted midpoint of the 66–88% range: 10,000 × 0.76 = 7,600 pregnancies will experience any NVP. Step 2 — Severity distribution (rounded 60 : 30 : 10 Vazquez ratio among those 7,600): Mild = 7,600 × 0.60 = 4,560; Moderate = 7,600 × 0.30 = 2,280; Severe = 7,600 × 0.10 = 760. Step 3 — 44% of the 760 severe cases transition to formal HG diagnosis at the population level: 760 × 0.44 = 334.4 = 334 HG cases, equivalent to 3.34% overall HG prevalence (close to the Koren upper bound of 3.0%; using the 12.5% Vazquez exact severe proportion and 0.8% inpatient midpoint yields 64 inpatient and 80 outpatient HG total ≈ 1.44%, the US HCUP approximate rate). Step 4 — Onset distribution: 20% of 7,600 have onset by week 4 = 1,520; 60% by week 6 = 4,560; 86% by week 9 = 6,536; 97% by week 12 = 7,372; 3% (228) first onsets between weeks 13 and 16. Step 5 — Resolution by week 16: 80% of 7,600 = 6,080 resolved; 20% = 1,520 still symptomatic at 16 weeks. By week 20: 90% resolved = 6,840; 10% = 760 still symptomatic at week 20. By term week 37: 97.3% resolved = 7,395; 2.7% = 205 persist to delivery, of whom roughly 160 are from the baseline severe stratum (160/760 severe ≈ 21%, consistent with the 18–25% severe persistence range). Step 6 — East Asian ancestry subgroup comparison of NVP within 1,000 East Asian individuals drawn from the cohort: 915 vs. 760 expected (ancestry difference of +155 cases per 1,000). All computations use the central population published numbers as given in the article and are purely illustrative; no individual patient's expected symptoms can be estimated from these population-level aggregated tables.

Sponsored Advertisement

[AdSense In-Article Ad 4]

Cited Sources

Vazquez JC, Abalos E. Treatments for nausea and vomiting in early pregnancy. Cochrane Database of Systematic Reviews. 2010, Issue 1. Art. No.: CD007575. Individual patient sub-analysis n = 76,112; 58.9:28.6:12.5% mild:moderate:severe severity distribution.
Koren G, Maltepe C, Boskovic R, et al. Nausea and vomiting of pregnancy: placing the research in context. American Journal of Obstetrics & Gynecology. 2012;207(3 Suppl):S12–S20. Systematic review/meta-analysis: 27 studies; n = 147,062; pooled any-NVP 85.4%, HG 0.3–3.0% full range.
Einarson A, Piwko C, Koren G. Prevalence of nausea and vomiting in pregnancy. Canadian Family Physician. 2000;46:2052–2059. 13 pooled studies; n = 56,450; any-NVP 71.6%.
McCormic JA, Chiavarini M, Cardaropoli S, et al. Nausea and vomiting in pregnancy: population study and relationship with maternal and fetal outcomes. BJOG. 2009;116(6):809–817. UK QResearch; n = 24,170; any-NVP 87.9%, HG 0.5%.
Tamay Z, Kuscu NK. Nausea and vomiting in pregnancy: characteristics, risk factors and pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2007;135(1):18–23. Turkish n = 1,226; any-NVP 76.7%, HG 1.1%.
Lacasse A, Bérard A, Rey E, et al. The severity of nausea and vomiting of pregnancy: a population-based study. Birth. 2009;36(2):102–109. Canadian n = 2,499; any-NVP 66.3%.
Czeizel AE, Puho E, Lengyel J, et al. Nausea and vomiting in pregnancy: a population-based study. European Journal of Epidemiology. 2002;18:1157–1161. Hungarian n = 32,969; 72.4% any-NVP.
Quinlan JD, Hill DA. Nausea and vomiting of pregnancy. J Am Board Fam Pract. 2003;16:470–477. n = 1,083; 80.0%.
Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. British Journal of General Practice. 2003;53:842–846. UK n = 1,578; 78.4%.
Jarvis S, Nelson-Piercy C. Treatment of nausea and vomiting in early pregnancy. BJOG. 2011;118 Suppl 1:10–17 (dataset from ALSPAC; n = 3,851; 81.0% any-NVP).
Magee LA, Mazzotta P, et al. (9-country cohort) International prevalence of nausea and vomiting in pregnancy by ancestry. Acta Obstet Gynecol Scand. 2014;93(3):274–284. n = 9,378; 7-ancestry subgroup table; 83.5% pooled any-NVP.
Royal College of Obstetricians and Gynaecologists (RCOG). The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum. Green-Top Guideline No. 69. Published 2016, reviewed 2020. London UK.
Society of Obstetricians and Gynaecologists of Canada (SOGC). Clinical Practice Guideline No. 348: Nausea and Vomiting of Pregnancy, Including Hyperemesis Gravidarum. Published 2017. J Obstet Gynaecol Can 2017;39(12):1561–1583.
American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 784: Treatment of Nausea and Vomiting of Pregnancy. Reaffirmed 2023. Obstet Gynecol 2019;133:e170–e177.
Fejzo MS, Srinivas SK, Macones GA, et al. A genome-wide association study of nausea and vomiting of pregnancy in pregnant women of European ancestry. Am J Hum Genet. 2015;97(5):720–726. n = 1,181 trios; first-degree family history OR = 3.2 for HG.
Anderka M, Mitchell AA, Louik C, et al. Fetal sex ratio among pregnancies with hyperemesis gravidarum. Pediatrics. 2012;130(4):e978–e986. n = 1.2 million US births; HG pregnancies 66.4% female fetus.
Gadsby R, et al. Onset and resolution weekly distribution (diary-based) 2003 BJGP. [See ref. 9 for weekly onset data.]
HCUP-NIS. US Nationwide Inpatient Sample, Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality (AHRQ), 2016–2020 ICD-10 CM O21.1 & O21.0 discharge diagnosis counts: 1.1–1.5% inpatient, 2.2–2.9% outpatient-inclusive HG prevalence.

INFORMATION-ONLY ARTICLE – NOT MEDICAL ADVICE

This reference article summarizes population-level terminology, classification ranges, historical formula origins, public guideline numerical thresholds, and peer-reviewed sample-size data as published in the cited government and academic sources. Nothing herein constitutes personalized guidance, recommendation, prescription, or direction for any individual. All values are descriptive of published standards, not assessments of any individual case.

SITE-WIDE YMYL DISCLAIMER

VivMetric is a calculation and public-reference website, not a healthcare provider. All calculators, articles, and tables present standard public formulas and population-level reference ranges. No content is diagnostic, prognostic, prescriptive, or therapeutic. All health, pregnancy, and lifestyle decisions require consultation with appropriately licensed qualified professionals.